Thrivent Financial for Lutherans Sells 4,908 Shares of Enovis Co. (NYSE:ENOV)

Thrivent Financial for Lutherans decreased its holdings in Enovis Co. (NYSE:ENOV) by 0.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,819,873 shares of the company’s stock after selling 4,908 shares during the quarter. Thrivent Financial for Lutherans owned approximately 3.32% of Enovis worth $82,258,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of ENOV. Scout Investments Inc. acquired a new position in shares of Enovis during the first quarter worth approximately $6,116,000. Price T Rowe Associates Inc. MD lifted its holdings in Enovis by 88.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 381,118 shares of the company’s stock worth $23,802,000 after buying an additional 179,276 shares in the last quarter. UBS Group AG boosted its position in Enovis by 1,060.8% in the 4th quarter. UBS Group AG now owns 333,510 shares of the company’s stock valued at $18,683,000 after buying an additional 304,779 shares during the last quarter. Tributary Capital Management LLC increased its stake in shares of Enovis by 15.6% in the 1st quarter. Tributary Capital Management LLC now owns 338,371 shares of the company’s stock valued at $21,131,000 after buying an additional 45,745 shares during the period. Finally, Quadrature Capital Ltd raised its position in shares of Enovis by 175.5% during the fourth quarter. Quadrature Capital Ltd now owns 34,160 shares of the company’s stock worth $1,913,000 after acquiring an additional 21,760 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ENOV shares. JPMorgan Chase & Co. decreased their price target on Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Needham & Company LLC reduced their target price on shares of Enovis from $82.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, August 8th. Finally, Evercore ISI dropped their price target on shares of Enovis from $70.00 to $62.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $69.13.

Enovis Price Performance

Enovis stock opened at $43.67 on Friday. The firm has a market capitalization of $2.40 billion, a P/E ratio of -29.11 and a beta of 1.92. The business has a 50-day moving average of $44.73 and a 200-day moving average of $49.97. The company has a current ratio of 2.26, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. Enovis Co. has a 1 year low of $39.98 and a 1 year high of $65.03.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.03. The firm had revenue of $525.20 million during the quarter, compared to analysts’ expectations of $525.99 million. Enovis had a negative net margin of 4.73% and a positive return on equity of 4.06%. The business’s revenue for the quarter was up 22.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.61 earnings per share. On average, equities analysts anticipate that Enovis Co. will post 2.7 EPS for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.